Can DOTS control multidrug-resistant tuberculosis?

Lancet

Volumn 365, Issue 9466, 2005, Pages 1206-1209

  Espinal, Marcos A ^a   Dye, Christopher ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

DEATH; DISEASE CONTROL; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MEDICAL LITERATURE; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NOTE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT FAILURE; TUBERCULOSIS;

EID: 16344385633     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)74788-7     Document Type: Note

References (19)

1. MA Espinal, SJ Kim, PG Suarez Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries JAMA 283 2000 2537 2545
2. K Styblo, JR Bumgarner Tuberculosis can be controlled with existing technologies: evidence Tuberculosis Surveillance Res Unit Progress Rep 2 1991 60 72
3. C Dye, BG Williams, MA Espinal, MC Raviglione Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis Science 295 2002 2042 2046
4. T Cohen Modeling epidemics of multidrug-resistant M tuberculosis of heterogeneous fitness Nat Med 10 2004 1117 1120
5. SM Blower, T Chou Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance Nat Med 10 2004 1111 1116
6. KM Kam, CW Yip Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment Int J Tuberc Lung Dis 5 2001 815 823
7. YP Hong, SJ Kim, JY Bai, WJ Lew, EG Lee Twenty-year trend of chronic excretors of tubercle bacilli based on the nationwide tuberculosis prevalence surveys in Korea, 1975-1995 Int J Tuberc Lung Dis 4 2000 911 919
8. ML Garcia-Garcia, PM Small, C Garcia-Sancho Tuberculosis epidemiology and control in Veracruz, Mexico Int J Epidemiol 28 1999 135 140
9. ML Garcia-Garcia, DL Ponce, ME Jimenez-Corona Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico Arch Intern Med 160 2000 630 636
10. M Garcia-Garcia, M Palacios-Martinez, A Ponce-de-Leon The role of core groups in transmitting Mycobacterium tuberculosis in a high prevalence community in Southern Mexico Int J Tuberc Lung Dis 4 2000 12 17
11. MA Espinal, A Laszlo, L Simonsen Global trends in resistance to antituberculosis drugs N Engl J Med 344 2001 1294 1303
12. World Health Organization Global tuberculosis control: surveillance, planning, financing 2004 WHO Geneva http://www.who.int/tb/publications/ global_report/en (accesed Feb 7, 2005)
13. R Gupta, M Cegielski, M Espinal Increasing transparency for health - introducing the Green Light Committee Trop Med Int Health 7 2002 970 976
14. K Tahaoglu, T Torun, T Sevim The treatment of multidrug-resistant tuberculosis in Turkey N Engl J Med 345 2001 170 174
15. C Mitnick, J Bayona, E Palacios Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru N Engl J Med 348 2003 119 128
16. PG Suarez, K Floyd, J Portocarrero Feasibility and cost effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru Lancet 359 2002 1980 1989
17. A Van Deun, MA Salim, AP Das, I Bastian, F Portaels Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh Int J Tuberc Lung Dis 8 2004 560 567
18. Scientific Panel of the Working Group on DOTS-Plus for MDR-TB Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB) http://www.emro.who.int/stb/ technicalpapers/morocco03/GUIDELINESDOTS.pdf 2000 (accesed Feb 7, 2005)
19. V Leimane, V Riekstina, TH Holtz Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia, 2000: a retrospective cohort study Lancet 365 2005 318 326